Abstract：
Alzheimer\'s disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid - β extracellular plaques and tau interfibrillar tangles, leading to memory loss, cognitive decline, and behavioral changes. With dementia posing a growing global health concern, there is an urgent need for comprehensive strategies to address its challenges. The economic burden of dementia is projected to rise significantly, emphasizing the necessity for collaborative efforts in research and healthcare. In the United States alone, millions are affected by AD, with prevalence increasing with age and even affecting younger individuals. The complexity of AD involves intricate biological processes, including the aggregation of amyloid beta, oxidative stress, and metal ion dysregulation. Metal ions, particularly those from copper, iron, and zinc, play pivotal roles in AD pathology, influencing Aβ deposition and tau protein accumulation. Current treatments offer symptomatic relief but do not address the underlying disease mechanisms. This paper explores the potential of various chelating compounds to target metal ions involved in AD pathology. N-acylhydrazones, morpholine, chrysin, quinoline, oxindole, cyclam, catechol-based, and quinazolinone-based derivatives show promising chelation activity and therapeutic effects. Metal chelation therapy offers a targeted approach to AD treatment by addressing the core pathology. By selectively binding to metal ions implicated in disease progression, chelators may minimize side effects associated with broad-spectrum treatments. Additionally, chelators may offer neuroprotective effects beyond metal binding, further enhancing their therapeutic potential. Overall, metal chelation therapy presents a promising strategy in combating AD, with the potential to significantly impact disease progression and improve patient outcomes.
摘要：
阿尔茨海默病（AD）是一种神经退行性疾病，其特征是淀粉样β细胞外斑块和tau纤维间缠结的积累，导致记忆丧失,认知能力下降,和行为变化。随着痴呆症日益引起全球健康关注，迫切需要全面的战略来应对其挑战。痴呆症的经济负担预计将大幅上升,强调在研究和医疗保健方面进行合作的必要性。仅在美国，数百万人受到AD的影响，患病率随着年龄的增长而增加，甚至影响年轻人。AD的复杂性涉及复杂的生物过程，包括β淀粉样蛋白的聚集，氧化应激，和金属离子失调.金属离子,特别是那些来自铜的，铁,还有锌,在AD病理学中起关键作用，影响Aβ沉积和tau蛋白积累。目前的治疗提供症状缓解，但不能解决潜在的疾病机制。本文探讨了各种螯合化合物靶向涉及AD病理的金属离子的潜力。N-酰腙,吗啉,chrysin,喹啉,羟吲哚,cyclam,基于邻苯二酚，和基于喹唑啉酮的衍生物显示出有希望的螯合活性和治疗效果。金属螯合疗法通过解决核心病理为AD治疗提供了靶向方法。通过选择性结合与疾病进展有关的金属离子，螯合剂可以减少与广谱治疗相关的副作用。此外,螯合剂可以提供超越金属结合的神经保护作用，进一步增强他们的治疗潜力。总的来说,金属螯合疗法在对抗AD方面提出了一种有希望的策略，具有显著影响疾病进展和改善患者预后的潜力。
